MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing a voice-based artificial intelligence platform designed to detect drug and alcohol impairment in real time from short speech samples. The technology, trained on more than 50 million data points and analyzing over 140 acoustic markers, offers a non-invasive alternative to traditional breath, saliva, urine and laboratory-based testing. Initial field testing is planned for 2026, with a commercial focus on South American mining operations, where large-scale workforce screening presents significant safety and logistical challenges.
The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033, according to industry forecasts. MindBio sees opportunities to expand its platform into aviation, construction, transportation, law enforcement, call centers and healthcare, leveraging its proprietary research to address increasing demand for faster, scalable workplace impairment detection.
MindBio's AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication in a range of enterprise environments. For more details, the full article is available at https://ibn.fm/Gw5Fa.
The technology aims to deliver real-time impairment assessments through Edge AI kiosks, offering a faster and more scalable solution than current methods. As workplace safety regulations tighten and industries seek to reduce accidents caused by impairment, MindBio's voice-based analysis could provide a practical tool for frequent, non-invasive screening.
MindBio Therapeutics is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company's latest news and updates are available in its newsroom at https://ibn.fm/MBQIF.
This development matters because it represents a potential shift in how impairment is detected in the workplace, moving from invasive, time-consuming tests to a quick, voice-based method that could be deployed widely. If successful, the technology could improve safety in high-risk industries and reduce the burden of traditional testing.
